APP/PS1 mice expressed a chimeric mouse/human APP with the Swedish double mutations (K595N/M596L) and human presenilin 1 with the exon 9 deletion, developing Aβ deposits as early as 4 months of age and cognitive deficits by 6 months of age.[51, 52] VUF6002 treatment completely reversed their cognitive deficits, as demonstrated in the Y‐Maze (Figure S7C, Supporting Information), NOR (Figure S7D, Supporting Information), and Morris water maze (MWM) (Figure S7E, Supporting Information). The gene discussed is PSEN1; the disease is Cognitive impairment.